دورية أكاديمية
Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus.
| العنوان: | Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus. |
|---|---|
| المؤلفون: | Diaz-Cánova D; Molecular Inflammation Research Group, Department of Medical Biology, UiT - The Arctic University of Norway, Tromsø, Norway., Moens U; Molecular Inflammation Research Group, Department of Medical Biology, UiT - The Arctic University of Norway, Tromsø, Norway., Brinkmann A; WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute, Berlin, Germany., Nitsche A; WHO Reference Laboratory for SARS-CoV-2 and WHO Collaborating Centre for Emerging Infections and Biological Threats, Robert Koch Institute, Berlin, Germany., Okeke MI; Section of Biomedical Sciences, Department of Natural and Environmental Sciences, School of Arts and Sciences, American University of Nigeria, Yola, Nigeria. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Apr 03; Vol. 15, pp. 1277447. Date of Electronic Publication: 2024 Apr 03 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Influenza Vaccines*/genetics , Coinfection* , Superinfection*, Chlorocebus aethiops ; Animals ; Cats ; Humans ; Cowpox virus/genetics ; Vero Cells ; Vaccinia virus ; Vaccines, Synthetic/genetics ; Whole Genome Sequencing |
| مستخلص: | Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as recombinant vector vaccine against infectious diseases and cancers in humans and animals. However, one biosafety concern about the use of MVA vectored vaccine is the potential for MVA to recombine with naturally occurring orthopoxviruses in cells and hosts in which it multiplies poorly and, therefore, producing viruses with mosaic genomes with altered genetic and phenotypic properties. We previously conducted co-infection and superinfection experiments with MVA vectored influenza vaccine (MVA-HANP) and a feline Cowpox virus (CPXV-No-F1) in Vero cells (that were semi-permissive to MVA infection) and showed that recombination occurred in both co-infected and superinfected cells. In this study, we selected the putative recombinant viruses and performed genomic characterization of these viruses. Some putative recombinant viruses displayed plaque morphology distinct of that of the parental viruses. Our analysis demonstrated that they had mosaic genomes of different lengths. The recombinant viruses, with a genome more similar to MVA-HANP (>50%), rescued deleted and/or fragmented genes in MVA and gained new host ranges genes. Our analysis also revealed that some MVA-HANP contained a partially deleted transgene expression cassette and one recombinant virus contained part of the transgene expression cassette similar to that incomplete MVA-HANP. The recombination in co-infected and superinfected Vero cells resulted in recombinant viruses with unpredictable biological and genetic properties as well as recovery of delete/fragmented genes in MVA and transfer of the transgene into replication competent CPXV. These results are relevant to hazard characterization and risk assessment of MVA vectored biologicals. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Diaz-Cánova, Moens, Brinkmann, Nitsche and Okeke.) |
| References: | Viruses. 2018 May 12;10(5):. (PMID: 29757202) Viruses. 2017 Jun 10;9(6):. (PMID: 28604604) Infect Genet Evol. 2013 Mar;14:406-25. (PMID: 23268114) Front Microbiol. 2022 May 03;13:868887. (PMID: 35592007) Virology. 1990 Jan;174(1):35-42. (PMID: 2294646) J Virol. 2000 Dec;74(24):11654-62. (PMID: 11090164) Virology. 1997 Nov 24;238(2):198-211. (PMID: 9400593) Lancet. 2013 Mar 23;381(9871):1021-8. (PMID: 23391465) AIDS Res Hum Retroviruses. 2005 Jan;21(1):98-102. (PMID: 15665649) Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13757-62. (PMID: 11717435) Emerg Infect Dis. 2009 May;15(5):777-80. (PMID: 19402967) J Virol. 2010 Aug;84(16):8141-52. (PMID: 20534857) Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. (PMID: 18678911) Emerg Infect Dis. 2015 Apr;21(4):695-8. (PMID: 25811411) PLoS One. 2015 Apr 14;10(4):e0118486. (PMID: 25874723) J Gen Virol. 2011 Sep;92(Pt 9):1971-1980. (PMID: 21715594) Viruses. 2019 Aug 01;11(8):. (PMID: 31375015) J Infect Dis. 2015 Apr 1;211(7):1076-86. (PMID: 25336730) J Virol. 1992 Apr;66(4):2076-85. (PMID: 1548753) Viruses. 2020 Nov 05;12(11):. (PMID: 33167496) J Virol. 2021 Jun 24;95(14):e0031821. (PMID: 33910949) JAMA. 2016 Apr 19;315(15):1610-23. (PMID: 27092831) Bioinformatics. 2000 Jun;16(6):562-3. (PMID: 10980155) Mol Biol Evol. 2013 Apr;30(4):772-80. (PMID: 23329690) Virol J. 2009 May 12;6:55. (PMID: 19435511) Am J Infect Control. 1982 May;10(2):53-9. (PMID: 7044193) Traffic. 2008 Aug;9(8):1283-98. (PMID: 18485055) J Gen Virol. 1998 Feb;79 ( Pt 2):347-52. (PMID: 9472619) Vaccines (Basel). 2022 Sep 13;10(9):. (PMID: 36146594) Mol Biol Evol. 2010 Sep;27(9):2038-51. (PMID: 20363828) Virus Genes. 2017 Dec;53(6):883-897. (PMID: 28762208) Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3759-3767. (PMID: 32019881) Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8348-53. (PMID: 12034885) Expert Rev Vaccines. 2016;15(1):91-103. (PMID: 26511884) Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51. (PMID: 1438287) J Virol. 1988 Feb;62(2):367-75. (PMID: 2826801) Virology. 1999 Dec 20;265(2):218-25. (PMID: 10600594) BMC Genomics. 2006 Jun 13;7:150. (PMID: 16772042) J Gen Virol. 2004 Jan;85(Pt 1):105-117. (PMID: 14718625) Virology. 1992 Aug;189(2):678-86. (PMID: 1641985) Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):423-30. (PMID: 12818626) Virus Evol. 2015 May 26;1(1):vev003. (PMID: 27774277) AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. (PMID: 24090081) Int J Infect Dis. 2021 Mar;104:239-241. (PMID: 33359672) J Virol. 2014 Sep 1;88(17):9751-68. (PMID: 24920806) Virus Genes. 2011 Apr;42(2):171-7. (PMID: 21153876) Viruses. 2022 Sep 28;14(10):. (PMID: 36298689) J Gen Virol. 1998 May;79 ( Pt 5):1159-67. (PMID: 9603331) Wilderness Environ Med. 2021 Dec;32(4):528-536. (PMID: 34563454) Curr Opin Virol. 2018 Feb;28:108-115. (PMID: 29288901) J Virol. 1999 Jan;73(1):152-60. (PMID: 9847317) Lancet Infect Dis. 2014 Dec;14(12):1196-207. (PMID: 25455987) Genetics. 2007 Jun;176(2):1035-47. (PMID: 17409078) Bioinformatics. 2002 Nov;18(11):1544-5. (PMID: 12424130) Viruses. 2010 Sep;2(9):1933-1967. (PMID: 21994715) Mol Biol Cell. 2001 Jul;12(7):2031-46. (PMID: 11452001) Viruses. 2015 Apr 07;7(4):1726-803. (PMID: 25853483) J Gen Virol. 2014 Feb;95(Pt 2):466-471. (PMID: 24145605) Emerg Infect Dis. 2013 Dec;19(12):1996-9. (PMID: 24274113) Clin Infect Dis. 2017 Jun 15;64(12):1737-1741. (PMID: 28329402) Nat Rev Microbiol. 2022 Sep;20(9):507-508. (PMID: 35859005) PLoS One. 2014 Sep 25;9(9):e107903. (PMID: 25254500) Infect Genet Evol. 2012 Jan;12(1):160-8. (PMID: 21983687) N Engl J Med. 2019 Nov 14;381(20):1897-1908. (PMID: 31722150) J Gen Virol. 1991 May;72 ( Pt 5):1031-8. (PMID: 2033387) Vaccine. 1994 Aug;12(11):1032-40. (PMID: 7975844) Lancet Infect Dis. 2020 Jul;20(7):827-838. (PMID: 32325037) Pediatr Nephrol. 2017 Mar;32(3):533-536. (PMID: 27796621) PLoS One. 2018 Feb 20;13(2):e0192312. (PMID: 29462200) Antiviral Res. 2009 Oct;84(1):1-13. (PMID: 19563829) J Virol. 2011 Dec;85(24):13049-60. (PMID: 21976639) PLoS One. 2014 Mar 13;9(3):e91520. (PMID: 24626337) Lancet Infect Dis. 2016 Jan;16(1):31-42. (PMID: 26546548) J Virol. 1993 Jun;67(6):3319-25. (PMID: 8497053) J Virol. 2014 May;88(10):5277-86. (PMID: 24574414) Scand J Infect Dis. 1998;30(3):301-3. (PMID: 9790141) Vaccine. 2009 Dec 9;27(52):7442-50. (PMID: 19539582) J Comput Biol. 2012 May;19(5):455-77. (PMID: 22506599) Berl Munch Tierarztl Wochenschr. 1994 Aug;107(8):253-6. (PMID: 7945180) Virology. 1994 Oct;204(1):376-90. (PMID: 8091668) Ann Intern Med. 2020 Mar 3;172(5):306-316. (PMID: 32040960) Viruses. 2017 Oct 29;9(11):. (PMID: 29109380) DNA Res. 2014 Dec;21(6):673-83. (PMID: 25267831) J Virol. 1998 May;72(5):4192-204. (PMID: 9557708) Virus Res. 2009 Oct;145(1):54-62. (PMID: 19540275) Curr Gene Ther. 2013 Dec;13(6):413-20. (PMID: 24397528) Virology. 1998 May 10;244(2):365-96. (PMID: 9601507) Emerg Infect Dis. 2021 Oct;27(10):2570-2577. (PMID: 34352194) J Infect Dis. 2020 Aug 4;222(5):807-819. (PMID: 31740938) Science. 2010 Feb 12;327(5967):873-876. (PMID: 20093437) J Gen Virol. 2006 Jan;87(Pt 1):21-27. (PMID: 16361414) J Infect Dis. 2021 Mar 29;223(6):1062-1072. (PMID: 32726422) J Virol. 2015 Feb;89(3):1809-24. (PMID: 25410873) Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90. (PMID: 219640) Vaccine. 2004 Dec 9;23(4):499-506. (PMID: 15530698) Virology. 2014 May;456-457:145-56. (PMID: 24889234) Med Mal Infect. 2018 Jun;48(4):263-268. (PMID: 29573840) Bioinformatics. 2000 Jul;16(7):573-82. (PMID: 11038328) N Engl J Med. 2015 Mar 26;372(13):1223-30. (PMID: 25806914) iScience. 2020 Mar 27;23(3):100920. (PMID: 32145646) J Virol. 2002 Nov;76(22):11637-44. (PMID: 12388724) Viruses. 2020 Dec 30;13(1):. (PMID: 33396609) Emerg Infect Dis. 2017 Dec;23(12):1941-1949. (PMID: 28975882) J Gen Virol. 1992 Mar;73 ( Pt 3):549-57. (PMID: 1545218) J Mol Evol. 1992 Feb;34(2):126-9. (PMID: 1556748) Virology. 1999 May 10;257(2):511-23. (PMID: 10329561) Emerg Infect Dis. 2019 Feb;25(2):212-219. (PMID: 30666929) |
| فهرسة مساهمة: | Keywords: orthopoxvirus; poxvirus; recombination; smallpox; superinfection exclusion |
| المشرفين على المادة: | 0 (Influenza Vaccines) 0 (Vaccines, Synthetic) |
| SCR Organism: | Modified Vaccinia Ankara virus |
| تواريخ الأحداث: | Date Created: 20240418 Date Completed: 20240419 Latest Revision: 20240425 |
| رمز التحديث: | 20240425 |
| مُعرف محوري في PubMed: | PMC11021749 |
| DOI: | 10.3389/fimmu.2024.1277447 |
| PMID: | 38633245 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1277447 |